Immix Biopharma Inc. (IMMX)
IMMX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IMMX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001873835 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $320.3M cash; operating cash flow -$11.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 83,812,456 (2026-10-30); 33,577,873 a year earlier; 19,867,224 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-09-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Crowe LLP, Los Angeles, California, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $10K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$13.9M | -$12.3M | $320.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$11.6M | -$11.7M | $225.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$10.1M | -$9.8M | $79.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$10.6M | -$11.0M | $93.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2025 2025-09-30 | Not filed | -$7.6M | -$5.9M | $15.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$6.6M | -$5.3M | $11.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$4.5M | -$1.7M | $15.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$4.8M | -$1.5M | $17.7M | No debt tags | Needs four quarters | 10-K/A 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-29 |
| Latest annual report | 10-K/A | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.7% |
| 1 month | -9.8% |
| 3 months | -28.2% |
| Year to date | +49.9% |
| 1 year | +117.2% |
| From 52-week high | -45.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corporation | $4.04 | -1.22% | $619.3M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| GERN | Geron Corporation | $0.9419 | -2.60% | $606.8M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier